Raregivers Inc., Havas Health Network and director Bryan Buckley have partnered on The Rare Truth, a global PSA campaign launching November 10 that centers real caregiver stories from around the world.
Read the story
South Korea's ISO EV is widening its distribution from body composition analyzers to AI-powered 3D skin analyzers, with EVE MUSE and EVE YOUNG targeting clinics, retailers and salons worldwide. The company reports rising exports and new franchise partners across Asia, Europe and the Middle East.
Suzhou Ribo Life Science and subsidiary Ribocure Pharmaceuticals have submitted a Phase I clinical trial application in the EU for SR122, a dual GalNAc conjugated siRNA targeting ApoC3 and PCSK9 for dyslipidemia. The randomized, placebo-controlled study will assess safety, tolerability, pharmacokinetics and pharmacodynamics in healthy participants.
A new IFAD report identifies El Niño among overlapping climate and economic shocks affecting small-scale food producers, while UN teams respond to displacement in Mozambique and a measles-rubella campaign in Yemen.
Nearly 200 countries have gathered in Antalya for COP31, with finance access, emissions reductions and a just transition topping the agenda. The summit opens under pressure to convert decades of climate commitments into practical results.
Laboratoires Pierre Fabre and XtalPi have signed an agreement to collaborate on discovering novel clinical candidates in oncology, potentially dermatology, and rare diseases. XtalPi will apply its AI and robotics platform to design small molecule therapeutics against undisclosed targets.
Vinamilk's Optimum Gold has been named Brand of the Year in the Infant Formula category at the World Branding Awards 2026-2027, the only Vietnamese winner in its category. The award was presented at Hampton Court Palace in the United Kingdom.
A World Meteorological Organization report says record global temperatures will persist through 2026 as a powerful El Niño intensifies, warning of worsening heatwaves, floods and health risks ahead of COP31 talks in Türkiye.
PharmaBlock hosted its CMC Lifecycle Strategy Forum in Nanjing on November 5 and 6, gathering drug development experts to discuss how stage-appropriate CMC strategies can improve development efficiency and program readiness.
